Advaxis, Inc. (NASDAQ:ADXS) Earns Buy Rating from HC Wainwright

Advaxis, Inc. (NASDAQ:ADXS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday, November 8th. They currently have a $23.00 target price on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on ADXS. BidaskClub raised shares of Advaxis from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $19.00 price target on shares of Advaxis in a research note on Monday, September 25th.

Advaxis (NASDAQ:ADXS) traded up $0.02 on Wednesday, reaching $3.06. 382,722 shares of the company’s stock traded hands, compared to its average volume of 694,068. Advaxis has a 1 year low of $2.83 and a 1 year high of $10.06.

Advaxis (NASDAQ:ADXS) last announced its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.43 million. equities analysts forecast that Advaxis will post -2.21 EPS for the current year.

In other Advaxis news, insider Robert Petit sold 12,625 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,273.75. Following the completion of the transaction, the insider now owns 237,265 shares of the company’s stock, valued at approximately $756,875.35. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Sara Bonstein sold 12,734 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,621.46. Following the completion of the transaction, the chief financial officer now directly owns 244,504 shares of the company’s stock, valued at approximately $779,967.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,872,291 shares of company stock worth $8,163,810. 7.21% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the business. Cutler Capital Management LLC increased its position in shares of Advaxis by 150.0% during the 3rd quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 30,000 shares during the last quarter. Stonebridge Capital Management Inc. increased its position in shares of Advaxis by 88.7% during the 3rd quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 20,045 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Advaxis by 10.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 2,969 shares during the period. State Street Corp boosted its stake in Advaxis by 7.8% in the 2nd quarter. State Street Corp now owns 670,134 shares of the biotechnology company’s stock worth $4,352,000 after purchasing an additional 48,485 shares during the period. Finally, DAFNA Capital Management LLC boosted its stake in Advaxis by 43.6% in the 2nd quarter. DAFNA Capital Management LLC now owns 247,000 shares of the biotechnology company’s stock worth $1,603,000 after purchasing an additional 75,000 shares during the period. 44.07% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Advaxis, Inc. (NASDAQ:ADXS) Earns Buy Rating from HC Wainwright” was reported by BBNS and is owned by of BBNS. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://baseballnewssource.com/markets/advaxis-inc-adxs-receives-buy-rating-from-hc-wainwright/1766307.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.